期刊
JOURNAL OF SUBSTANCE ABUSE TREATMENT
卷 34, 期 2, 页码 147-156出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jsat.2007.02.004
关键词
pharmacotherapy; cost sharing; pharmacy benefits; formulary; substance abuse
资金
- NIAAA NIH HHS [R01 AA010869, R01 AA010869-06] Funding Source: Medline
- NIDA NIH HHS [P50 DA010233-09, R01 DA10915, R01 DA010915, P50 DA010233, R01 DA010915-05] Funding Source: Medline
Health plans have implemented cost sharing and administrative controls to constrain escalating prescription expenditures. These policies may impact physicians' prescribing and patients' use of these medications. Important clinical advances in the pharmacological treatment of addiction highlight the need to examine how pharmacy benefits consider medications for substance dependence. The extent of restrictions influencing the availability of these medications to consumers is unknown. We use nationally representative survey data to examine the extent and stringency of private health plans' management of naltrexone and disulfiram for alcohol dependence, and buprenorphine for opiate dependence. Thirty-one percent of insurance products excluded buprenorphine from formularies, whereas 55% placed it on the highest cost-sharing tier. Generic naltrexone is the only substance dependence medication that is both rarely excluded from formularies and usually placed on a lower cost-sharing tier. These findings demonstrate that pharmacy benefits have an impact on access to medications for substance abuse. (C) 2008 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据